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imidazolium amphiphiles: synthesis, cytotoxicity
and incorporation onto gold nanoparticles†
M. Rodrigues,a L. Russo,a E. Aguilo´,b L. Rodr´ıguez,b I. Ottc and L. Pe´rez-Garc´ıa‡*a
A gold(I) N-heterocyclic carbene 4 from a bis-imidazolium-amphiphile was synthesized and characterized.
The cytotoxicity against HT-29 colon carcinoma and MDA-MB-231 breast adenocarcinoma cells was
assessed for the NHC complex 4, the imidazolium salt precursor 2, and its methyl analogue 3, indicating
that compounds 2–4 are promising cytotoxic agents. Furthermore, the ability of these compounds to be
associated with gold nanoparticles was also explored, in order to develop an anticancer drug delivery
system. The free ligands displayed more activity when compared with the ligands immobilized on the
gold nanoparticles. The synthesized gold particles incorporating the bis-imidazolium salts either 2 or 3
showed monodisperse spherical shape with sizes of approximately 5 nm.Introduction
One of the most urgent and challenging objectives of medicinal
chemistry is the discovery of novel and more eﬀective drugs for
ghting cancer. Bioinorganic and bio-organometallic chemistry
provides diﬀerent examples of metal complex-based drugs
whose tumour activity is well known: among them, cisplatin1 is
one of the most frequently used clinical anticancer drugs. The
gold compound auranon2,3 represents an important milestone
in the development of anticancer drugs based on Au(I)–phos-
phine complexes.4 Other phosphine–Au(I) derivatives with
anticancer activity include phosphine–Au(I)–thiolates, phos-
phine–Au(I)–phosphines, phosphine–Au(I)-alkynyls or phos-
phine–Au(I)-halides.4 Some phosphine–Au(I)-alkynyl derivatives
present higher activity than cisplatin in human ovarian cancer
cells5 and on Hep3B hepatocellular carcinoma cells.6
Thioredoxin reductase (TrxR) is an important and ubiqui-
tous enzyme critically involved in the regulation of intracellular
metabolism. The thioredoxin/thioredoxin reductase system
plays an important role in the redox state of the cells, besides
being involved in other cell functions such as cell proliferation,
transcription factor regulation or apoptosis.7 Inhibition of thiserape`utica and Institut de Nanocie`ncia i
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tion (ESI) available. See DOI:
e University of Nottingham, Universitysystem causes oxidized thioredoxin to accumulate in cells,
promoting apoptosis, thus making thioredoxin reductase
a good target for cancer therapy.8,9 In this context, increasing
interest has grown towards the development of inhibitors based
on lipophilic Au(I) complexes.10 These complexes are a very
promising class of non-platinum based antitumor agents, and
among them neutral and cationic complexes with N-
heterocyclic carbenes (NHCs) as ligands show a remarkable
strong anti-cancer eﬀect through the inhibition of Trx/TrxR
reductase system.10 Recent results indicate that TrxR inhibi-
tion in combination with antimitochondrial eﬀects are key
properties that determine the bioactivity of gold NHC
complexes. This therapeutic strategy exploits the negative
mitochondrial membrane potentials to selectively concentrate
delocalised lipophilic cations, such as Au(I) complexes, within
the organelle. In addition, the gold complex provides the
compound the ability to selectively coordinate the enzyme's
functional selenocysteine, increasing its anti-tumour activity.10
N-Heterocyclic carbenes (NHC) metal complexes11,12 are
known and studied as potential anticancer metallodrugs
because, compared with traditional gold complexes such as
auranon, they show an enhanced stability of the coordinative
bond with the metal atom and therefore they likely do not
undergo fast metabolization before reaching their enzymatic
target.13 Despite the similarities with the well-known phos-
phine–gold complexes,4 NHC ligands represent a better alter-
native due to their stability, as well as the ease with which it can
be functionalized in order to vary their lipophilicity. Nowadays,
diﬀerent groups concentrate their investigation on developing
novel gold NHC complexes with anti-cancer properties. Schuh
et al. successfully synthesized a family of substituted imidazole
and benzimidazole asymmetric Au(I) linear NHCs, evaluating
both their antiproliferative eﬀects on human ovarian cancer cellThis journal is © The Royal Society of Chemistry 2016
Scheme 1 Synthesis of imidazolium-based compounds 2 and 3,
formation of the carbene complex 4 and attempt of the formation of
complex 5 with phosphine–Au(I)-alkynyl derivative.
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type of NHC–Au–L compounds, Rubbiani et al. compared the
eﬀect of diﬀerent ligand L (L ¼ –Cl, –NHC, or –PPh3) on TrxR
inhibition and antimitochondrial action,15 showing how both
the cationic character and the modulation of the stability of the
coordinative bond of the complexes are key features for their
cytotoxicity. Liu et al. also provides a further example of a dia-
rylimidazole-based gold NHCs, in which a correlation between
complexes' biological activity and both the inactive, non-NHC
ligand and the aromatic substituents can be established.16 We
have also described the synthesis of Au(I) N-heterocyclic mon-
ocarbenes and dicarbenes derived from imidazolium salts, their
biological activity and TrxR inhibition ability.17
Moreover, recent works provide evidence of the wide range of
functionalities that can be introduced in this class of hetero-
cyclic compounds in order to further investigate their antitumor
activity: Pratesi et al.18 explored the inhibition mechanism of
TrxR by successfully coupling three diﬀerent Au(I)–NHC
complexes with a synthetic dodecapeptide containing a seleno-
cysteine group, conrming the direct coordination of this thiol-
residue with the gold atom. Citta et al. took advantage of the
ease of modication of NHCs for providing their complexes
with a uorescent anthracene unit. This functionalization not
only does not aﬀect the gold compound's antiproliferative
eﬀect, but also allows the study of its distribution in vivo.19
In our group, a class of gemini-type imidazolium surfactants
has been extensively studied because of its anion recognition
properties20,21 as well as its capability of stabilizing gold nano-
particles (AuNPs) synthesized in a biphasic system.20,22 The
amphiphilic bis-imidazolium compounds play a double role in
the synthesis, acting as transfer agents and stabilizers.
Furthermore, their anion recognition ability allowed the AuNPs
to incorporate successfully a model anionic drug and release it
in a sustained manner. Additionally, by changing the synthetic
method, we were able to produce amphiphiles bilayer-coated
water-soluble AuNPs that could load and deliver piroxicam, an
anti-inammatory drug with poor water solubility.23 Therefore,
these imidazolium-basedmolecules are promisingmaterials for
biomedical applications.24 It would be interesting to go one step
further and add a novel role to these molecules by introducing
a metal complex with gold moiety, thus achieving AuNPs that
would have not only the ability to carry drugs, but also present
biological activity due to the presence of the N-heterocyclic
carbenes (NHC) metal complex. The strategy to achieve this
goal would include synthesizing the NHC–Au(I) complex, but
also to take advantage of the versatility of these molecules,
a propargyloxy group was introduced in order to allow the
formation of a phosphine–Au(I)-alkynyl derivative.
Thus, in this study we develop the synthesis of novel bis-
imidazolium Au(I) carbene complexes as multifunctional
ligands for the synthesis of AuNPs with potential anticancer
activity, and we report: (a) the synthesis and structural charac-
terization of a bis-imidazolium gold(I) complex, (b) the
synthesis and morphological characterization of AuNPs,
bearing diﬀerent kinds of bis-imidazolium amphiphilic ligands
as stabilizing agents, and (c) the evaluation of the biological
activity of both the ligands and AuNPs.This journal is © The Royal Society of Chemistry 2016Results and discussion
Synthesis of Au(I) complexes
The reaction of DBMPB25 with N-octadecylimidazole (1a)20 or 2-
methyl-N-octadecylimidazole (1b) following a similar protocol
allowed obtaining the two bis-imidazolium amphiphiles 2 and 3
respectively (Scheme 1) in almost quantitative yields.
Two parallel strategies were then followed in order to obtain
the imidazolin-2-ylidene-Au(I) complex 4 (Scheme 1). The aim
was to direct selectively the ligand substitution reaction of the
gold precursor towards one precise functional group by varying
the reaction conditions and reagents. In the rst strategy, by
following a general procedure described in literature,26 weRSC Adv., 2016, 6, 2202–2209 | 2203
RSC Advances Papertargeted the acidic proton of the imidazolium rings, in order to
form a neutral heterocyclic carbene (NHC) as a coordinating
reactive site. Compound 4 was successfully synthesized by the
reaction of [AuCl(SMe2)] with 2, deprotonated in situ with
lithium bis(trimethylsilyl)amide (LiHMDS) in anhydrous
acetonitrile.11 This procedure provided selective conditions for
the synthesis of the Au(I)-carbene complex 4, obtained as a col-
ourless solid by recrystallization from acetone–hexane or
ethanol–diethylether with a 40% yield. The second strategy
focused on targeting the terminal alkyne of the propargylic
ether by deprotonating it in situ with potassium hydroxide,
promoting the coordination with a gold-1,3,5-triaza-7-
phosphaadamantane-chloride complex [AuCl(PTA)].27 Despite
the relatively mild basic environment, deprotonation was not
obtained selectively on the propargylic ether of compound 2 but
a competition with the imidazolium acidic proton was
observed. Various obstacles during purication were encoun-
tered, probably due to the lack of regioselectivity, thus an
univocal structure was not identied. To solve this inconve-
nience, the same reaction was carried out on themethylated bis-
imidazolium ligand 3, in an attempt to obtain the complex 5
incorporating a phosphine–Au(I)–alkyinyl derivative. However
due to the tendency towards aggregation caused by the bulky
PTA ligand, the desired gold complex could not be isolated in its
pure form and consequently was not successfully characterized.
Compounds 2, 3 and 4 were characterized by 1H NMR
spectroscopy. The corresponding spectroscopy data is summa-
rized in Table 1.
While both the imidazolium dications maintain similar
chemical shis for their analogous groups (for instance the
terminal alkyne proton peak at 2.64 ppm and 2.57 ppm respec-
tively), the imidazolium substituent R in position 2 was indicativeTable 1 1H NMR spectroscopic data from compounds 2–4
Compound
2 3 4
–CCH 2.64 2.57 2.71
–O–CH2– 4.45 4.79 4.61
–CH2– 5.57 5.62 5.20
Im–R(2) 10.44a 2.78b c
Im–H(4) 7.20 7.04 7.19
Im–H(5) 7.26 7.18 7.44
Ar-H(2) 7.76 7.21 7.09
Ar-(H4,6) 8.33 7.97 6.61
a R ¼ H. b R ¼ CH3. c R ¼ –Au(I)–; solvent: CDCl3.
2204 | RSC Adv., 2016, 6, 2202–2209for distinguishing between the two compounds. The formation of
Au(I) carbene complex 4 was also determined by 1H NMR spec-
troscopy (Table 1) by following the disappearance of the imida-
zolium acidic proton signal at 10.44 ppm, which might indicate
the coordinative bond formation between the imidazolium
dicarbene and the gold atom. The regioselectivity of the reaction
was proved since Au(I) compound spectra presented always the
peak corresponding to the alkynyl terminal proton at 3.53 ppm,
with a Dd ¼ +0.89 ppm compared to the starting material.
The structures of compounds 2 and 3 were also conrmed by
Electrospray Ionization Mass Spectrometry (ESI-MS) with both
presenting a main characteristic fragmentation ion corre-
sponding to the dication resulting of the loss of the two bromide
counterions [(M  2Br)/2]2+ (Table 2 and ESI, Fig. S1 and S2†).
Further conrmation of Au(I) carbene 4 was provided
through Matrix Assisted Laser Desorption Ionization Time-Of-
Flight Mass Spectrometry (MALDI-TOF MS) analysis which
showed, in the case of DHB-supported ionization, two main
peaks, the most abundant peak corresponding to bromide loss
(M Br)+ at 993.80m/z, in accordance with previously described
analogues,20 and the second peak from the simultaneous
bromide and propargyl loss (M  Br  CH2CCH)+ at 955.70 m/z
(see ESI, Fig. S3†). The measurement was also performed
without polymer matrix and the same main characteristic
signals were observed, together with peaks related to the
gradual fragmentation of the alkyl chains (see ESI, Fig. S4†).
There were however some diﬀerences observed in the abun-
dance of the obtained peaks: when the analysis was performed
without matrix, the most abundant peak corresponded to the
loss of bromide and propargyl, whereas in the case of the
analysis performed with matrix, the abundance is much lower
(25%), and the peak corresponding to the molecule with no loss
of bromide is also identied with low abundance (10%).Synthesis of gold nanoparticles (AuNPs)
Our group reported that bis-imidazolium derived gemini-type
surfactants are able to recognize anions,20–22 an interesting
feature that can be used in nanomedical applications, and
described how these molecules could also be used for the
synthesis and stabilization of AuNPs through amodication of the
Brust–Schiﬀrin method.20,22 The synthesis of AuNPs is achieved
through reduction of HAuCl4 with NaBH4 in a biphasic system, inTable 2 Positive-ion mode MS for compounds 2 and 3 and positive
mode MALDI-TOF-MS for compound 4
MWb
(g mol1)
Ionsa (m/z)
[(M  2Br)/2]2+ [M  Br]+ [M–Br–CH2CCH]+
2c 959.1 399.4 (100%)
3c 987.2 413.4 (100%)
4d 1074.2 993.8 (100%) 955.7 (25%)
4e 993.7 (75%) 955.7 (100%)
a Ions, m/z ratio relative abundance (%). b Molecular weight. c ESI-MS.
d MALDI-TOF-MS with matrix DHB. e MALDI-TOF-MS without matrix.
This journal is © The Royal Society of Chemistry 2016
Paper RSC Advanceswhich the imidazolium salts carry out both the functions of phase
transfer agent and stabilizer, besides maintaining the ability to
recognize and complexate anions, making them a promising tool
for delivery applications together with gold nanoparticles as drug
carriers.
Following the previously reported procedure, the nano-
particle synthesis was initially carried out successfully using the
free bis-imidazolium ligands 2 and 3 through the modied
Brust–Schiﬀrin method. The AuNPs formation was monitored
by UV-visible absorption spectroscopy, following the charac-
teristic Surface Plasmon Resonance (SPR) band at ca. 520 nm
(Fig. 1). The samples were further identied as 2$AuNP and
3$AuNP, respectively. Aer washing, the absorption spectrum
was compared to the free ligand, whose peaks at around l¼ 280
nm are clearly recognizable in the nanoparticles solution, con-
rming its presence as stabilizer.
Additionally, compound 2 and the corresponding 2$AuNP
sample were analysed by Infrared spectroscopy (IR) and it was
possible to identify the peaks of the ligand 2 on the AuNPs (see
ESI, Fig. S5 and S6†). The peaks corresponding to the C–H bond
in the imidazolium ring can be found around 3100 cm1 (being
less visible in the 2$AuNP spectrum). Two pronounced peaks,
corresponding to the CH2 from the alkyl chains are found at
2850 and 2920 cm1, around 2100 cm1 a peak assigned to the
C^C is found (also less pronounced in the 2$AuNP spectrum).
Between 1560 and 1650 cm1 three peaks, that can be assigned
to the C]C and C]N from the imidazolium moieties, are
found. Generally, the peaks of imidazolium salts are less
intense, especially the ones from the functional groups which
are somehow interacting with the metallic gold, such as the
phenyl ring and the alkine.
The synthesized AuNPs were observed by High Resolution
Transmission Electron Microscopy (HRTEM) to study their
morphology and size. The obtained micrographs can be seen inFig. 1 UV-visible absorption spectra of free ligand 2 (grey) and 2$AuNP
in CH2Cl2 (black). The peaks corresponding to the SPR band (523 nm)
and the imidazolium ligand (280 nm) are visible in the 2$AuNP
spectrum.
Fig. 2 HRTEM micrographs of 2$AuNP with (a) 30 000x and (b)
100 000x, magniﬁcation, and of 3$AuNP with (c) 25 000x and (d)
150 000x magniﬁcation, and their corresponding histograms.
This journal is © The Royal Society of Chemistry 2016 RSC Adv., 2016, 6, 2202–2209 | 2205
RSC Advances PaperFig. 2 and the size distribution can be observed in the corre-
sponding included histograms.
It is possible to identify relatively monodisperse spherical
particles with average diameter of 4.8  1.1 nm and 4.2  1.0
nm for 2$AuNP and 3$AuNP respectively.
By comparing the 2$AuNP and 3$AuNP nanoparticles,
formed with either imidazolium ligand 2 or 3, both TEM images
and UV-vis absorption spectroscopy did not provide any
evidence of relevant morphological diﬀerence, suggesting that
the introduction of a methyl chain in the imidazolium ring did
not aﬀect signicantly the ability of the ligand 3 to stabilize
AuNPs.
X-ray photoelectron spectroscopy (XPS) showed the presence
of two peaks at 84.2 eV and 87.8 eV (in the case of 2$AuNP) and
85.2 eV and 88.8 eV (in the case of 3$AuNP) corresponding to
Au4f7/2 and Au4f5/2 respectively. The peak position and the
distance between the two peaks (3.7 eV) is consistent with gold
in its reduced form Au(0) (see ESI, Fig. S7†) and is in agreement
with previously described bis-imidazolium coated nano-
particles.20 Furthermore, the presence of minor peaks corre-
sponding to Au(I), that can be found with a shi of 1–2 eV with
respect to the Au(0) peaks,28–30 were not identied during the
curve t of the XPS spectra, suggesting that no carbene species
were formed in situ during the AuNP synthesis, and that the
interaction between the ligand and the gold surface is not
mediated by carbenes.
The AuNPs were also analysed by X-ray diﬀraction (XRD) to
determine the phase composition. Four Bragg peaks could be
identied in the gold XRD pattern, indicating a face-centered
cubic (fcc) structure, with peaks at 37, 44, 65 and 78, cor-
responding respectively to (111), (200), (220) and (311) planes
(see ESI, Fig. S8†).
Thermogravimetric analysis was performed on 2$AuNP. The
data obtained for the amount of ligand present in the sample,
together with size data obtained from size measurements,
allowed the calculation of the number of ligands present in the
AuNPs (see ESI, Fig. S9 and Table S1†). It was possible to
determine that the AuNPs sample has approximately 24 ligands
per nm2. This value is in agreement with previous described
AuNPs with similar ligands, that present around 28–30 ligands
per nm2.22,23 This data also allows to determine the amount of
ligands present per gold nanoparticle, thus allowing to calculate
the approximate molecular weight of the whole nanostructure.Table 3 IC50 values in mM for cytotoxicity in HT-29 and MDA-MB-231
cell lines
IC50
a
HT-29 MDA-MB-231
2 7.4  0.6 12.1  2.4
3 6.3  1.5 9.4  1.0
4 >10 7.3  0.9
2$AuNP >0.0044 >0.0044
3$AuNP >0.0044 >0.0044
a Mean values of two to four independent experiments with errors.
2206 | RSC Adv., 2016, 6, 2202–2209Following these results, experiments were made to synthe-
size the Au(I)-complex directly on the formed 2$AuNP nano-
particles, with compound 2 as stabilizing agent. The goal was to
obtain the advantages of the gold nanoparticle as drug carrier,
and at the same time have a ligand with anticancer activity. To
perform the synthesis of the NHC metal complex, the same
procedure described in Scheme 1 was attempted, but the basic
medium caused the colloid to precipitate, and this approach
was discarded.Cytotoxicity study
The biological activity for the gold NHC 4 and for the bis-
imidazolium salt 2 and its methyl analogue 3 alone or conju-
gated with AuNP (2$AuNP and 3$AuNP) was evaluated. There-
fore, the cytotoxicity against tumour cell growth was determined
using the cell lines HT-29 (colon adenocarcinoma) and MDA-
MB-231 (breast adenocarcinoma). The antiproliferative activity
was expressed as IC50 values for cytotoxicity in both cell lines,
and the values are presented in Table 3.
From the above values it can be observed that the free
compounds do not follow a trend in the two studied cell lines as
the observed IC50 values are within a rather narrow range (6–13
mM). For complex 4, due to limited solubility this compound
could not be administered at concentrations higher than 10 mM,
and it was found that the IC50 against HT-29 cells is higher than
the maximum concentration tested.
The nanoparticles 2$AuNP and 3$AuNP were both applied at
maximum dosages of 0.0044 mM and did not display cytotoxicity
at this concentration. Using the data from the TGA analysis, it is
possible to determine the molecular weight of the AuNP and to
determine the amount of ligand present per mole of AuNP. The
calculations made show that to the applied concentration of
0.0044 mM of AuNP corresponds a concentration of 16 mM of
ligand. This value is similar to the IC50 found for the free
compounds, which means that when bound to the AuNPs, the
ligands do not present the same toxic eﬀect. However, since this
was the maximum concentration tested, it was not possible to
determine precisely the IC50 value of the ligand bound to the
AuNPs.
These ndings are in agreement with the results obtained
with a previously described analogue,20 also studied free and
conjugated to AuNPs, where we found a similar outcome. The
IC50 value (determined in Caco-2 cells) is similar to the one
found for these compounds, but the corresponding AuNPs
cytotoxicity was also higher than the maximum tested concen-
tration. Therefore, these results suggest that the ligands alone
present higher cytotoxicity, because they are more available for
interaction with the cells.Conclusions
In this work we describe the synthesis of two bis-imidazolium
precursors and a derived carbene complex, all showing cyto-
toxic eﬀect on two diﬀerent adenocarcinoma cell lines.
Furthermore, the bis-imidazolium complexes could be used
successfully to synthesize gold nanoparticles. However, whenThis journal is © The Royal Society of Chemistry 2016
Paper RSC Advancesincorporated on the AuNP no cytotoxicity was observed. This
behaviour was explained by the fact that the positive charges
from the polar head are not available to interact with the cells
because they are involved in the stabilization of the nano-
particles and hidden in the lipophilic layer. Further work
includes the formation of phosphine–Au(I)-alkynyl derivatives
with the alkyne moiety of ligands 2 and 3 aer the formation of
the gold nanoparticles, and also the formation of gold nano-
particles with the carbene complex 4.Experimental section
Materials
All solvents used were of analytical grade. Acetonitrile was dried
over basic aluminium oxide. Anhydrous tetrahydrofuran was
obtained through distillation over Na/benzophenone.
Commercial compounds: 1-bromooctadecane, chloro(dimethyl
sulde)gold(I), hydrogen tetrachloroaurate (III), lithium bis(-
trimethylsilyl)amide, 1,3,5-triaza-7-phosphaadamantane (PTA)
and sodium borohydride were purchased from Aldrich. 2-
Methylimidazole was purchased from Fluka. Potassium
hydroxide (KOH pellets) 85% was purchased from Scharlau.
CDCl3 was purchased from Euriso Top. Methods described in
literature were used to prepare 1,3-bisbromoethyl-5-
propargyloxybenzene (DBMPB)25 and N-octadecylimidazole.20General methods
1H NMR and 13C NMR were performed on Varian Gemini 300
and Varian Mercury 400 spectrometers from the Centres
Cient´ıcs i Tecnolo`gics de la Universitat de Barcelona (CCiT-
UB). NMR spectra were determined in CDCl3 and chemical
shis are expressed in parts per million (d) relative to TMS. Thin
layer chromatography was performed on Merck coated 60 F254
silica gel plates; the spots were located with UV light and
developed with an iodine/silica or 1% (w/v) potassium
permanganate solution. UV-visible absorption spectra were
determined in CH2Cl2 on a UV-1800 Shimadzu UV spectro-
photometer. ESI-MS was performed on a LC/MSD-TOF mass
spectrometer from Agilent Technologies: the nebulizing
nitrogen gas ow at 15 psi and drying nitrogen 7 L min1; the
source temperature was maintained at 300 C with a capillary
voltage of 4 kV and a fragment or voltage of 80 or 215 V. The
eluent owing through the probe was H2O : CH3CN (1 : 1) at
a ow rate of 200 mL min1. High resolution mass spectra (HR-
MS): electro-spray (ESI) with high resolution in Agilent (2006)
LC/MSD-TOF mass spectrometer. MALDI-TOF-MS were per-
formed on a 4800 Plus MALDI TOF/TOF mass spectrometer
from AB Sciex, from CCiT-UB. The laser operated at 355 nm, at
a frequency of 200 Hz and at a pulse of 3–7 ns. DHB (2,5-dihy-
droxybenzoic acid) was used as matrix. HRTEM images were
obtained using a JEOL JEM 2100 transmission electron micro-
scope at 200 kV, from CCiTUB. The images were captured by
a Megaview III So Imaging System camera, and the size of the
nanoparticles gold core was measured with ImageJ. TGA was
performed on aMettler Toledo TGA/SDTA 851e, at CCiTUB, with
a temperature ramp from 30 C to 600 C and a heating rate ofThis journal is © The Royal Society of Chemistry 201610 C min1. XPS analysis was carried out at CCiT-UB using
a Kratos Axis Ultra spectrometer with monochromatic Al Ka
(1486.6 eV, 10 mA, 15 kV) X-ray source and a power of 150 W.
Pressures near 1  108 Torr were observed in the analytical
chamber during surface analysis. All XPS analysis employed an
analysis area of 700 mm 300 mm. Survey spectra were recorded
using analyzer pass energy of 160 eV and a 1.0 eV energy step.
XRD measurements were performed with a Siemens D-5000 X-
ray diﬀractometer from the Scientic Experimental Platforms,
ICMAB-CSIC. The source was a DRX ceramic tube (l CuKa ¼
1.540560 A˚ and l CuKa2 ¼ 1.544390 A˚) with a voltage and
current of 45 kV and 35 mA, respectively. The AuNP samples
were placed on a glass slide and dried under vacuum, and were
scanned from 2q ¼ 30–80.Synthesis of compounds
2-Methyl-N-octadecylimidazole (1b). 1H-2-Methylimidazole
(0.87 g, 10.6 mmol) and potassium hydroxide (0.80 g, 12.8 mmol)
were stirred in dry CH3CN (52 mL) under argon atmosphere and
at room temperature until dissolved (2 hours). A solution of 1-
bromooctadecane (3.55 g, 10.6 mmol) in dry CH3CN at 40 C (36
mL) was added. Aer cooling down at room temperature, the
solution was stirred for 24 hours, and a white solid precipitated.
The solvent was evaporated, and the residue was partitioned
between CH2Cl2 (40 mL) and water (35 mL). The aqueous phase
was extracted with CH2Cl2 (2  40 mL), then the organic phases
were washed with water (70 mL), dried over MgSO4, ltered, and
the solvent was evaporated to obtain 1b as a yellow oil that
solidied at room temperature under vacuum (2.93 g, 82%).
1b. 1H NMR (300 MHz, CDCl3): 0.88 (t, J ¼ 6.8 Hz, 3H, –CH3);
1.25 (m, 30H, –(CH2)15–); 1.73 (m, 2H, –NCH2CH2–); 2.37 (s, 3H,
Im–CH3); 3.80 (t, J ¼ 7.2 Hz, 2H, –NCH2–); 6.80 (d, J ¼ 1.5, 1H,
Im–H); 6.90 (d, J ¼ 1.2, 1H, Im–H).
1,3-Bis[(3-octadecyl-1-imidazolio)methyl]-5-propargyloxybenzene
dibromide (2). A solution of DBMPB (0.30 g, 0.94 mmol) in dry
CH3CN (25 mL) was added to a solution of N-octadecylimidazole
(0.60 g, 1.89 mmol) in dry CH3CN (25 mL) at 80 C under argon
atmosphere, and the stirring was continued for 24 h. The yellow
solution was cooled down to room temperature and a white solid
precipitated. The solvent was evaporated completely and the
yellowish residue was suspended in hexane (8 mL), ltered and
washed with hexane, then the solid was dried in vacuum oven for 2
h. A white powder was obtained (0.88 g, 97%).
2. 1H NMR (300 MHz, CDCl3): 0.86 (t, J ¼ 6.3 Hz, 6H, –CH3);
1.26–1.32 (m, 60H, –(CH2)15–); 1.88 (m, 4H, –NCH2CH2–); 2.64 (t,
J¼ 2.3 Hz, 1H, –CCH); 4.24 (t, J¼ 7.5 Hz, 4H, –NCH2–); 4.45 (d, J
¼ 2.3 Hz, 2H, –OCH2–); 5.57 (s, 4H, –CH2–); 7.20 (s, 2H, Im–H);
7.26 (s, 2H, Im–H); 7.76 (s, 1H, Ar-H); 8.33 (s, 2H, Ar-H); 10.44 (s,
2H, Im–H). 13C (100 MHz, CDCl3): 14.3 (–CH2(CH2)13CH3); 32.1–
22.8 (–CH2(CH2)13CH3); 50.4 (–CH2(CH2)13CH3); 52.5 (–Ar-
CH2N–); 56.7 (–CH2–CCH); 76.8 (–CH2CCH); 116.5 (Im1); 121.6
(Im2); 123.7 (Ar2); 124.1 (Ar1); 136.2 (–ArCCH2N–); 137.0 (Im–
H); 158.3 (–ArCO–). IR: 2111 cm1 (v C–C, terminal alkyne). MS
(ESI) (m/z, %): 399.4, [(M  2Br)/2]2+, 100%. Rf: 0.5
(DCM : MeOH 95 : 5). mp: 160 C.RSC Adv., 2016, 6, 2202–2209 | 2207
RSC Advances Paper1,3-Bis[(3-octadecyl-2-methyl-1-imidazolio)methyl]-5-pro-
pargyloxybenzene dibromide (3). A solution of DBMPB (0.50 g,
1.60 mmol) in dry CH3CN (30 mL) was added to a solution of N-
octadecyl-2-methylimidazole (2) (1.10 g, 3.30 mmol) in the same
solvent (50 mL) at 80 C under argon atmosphere, and the
stirring was continued for 24 h. The yellow solution was cooled
down to room temperature and a white solid precipitated. The
solvent was evaporated completely and the yellowish residue
was suspended in hexane (8 mL), ltered and washed with
hexane, then the solid was dried in vacuum oven for 2 h. A white
powder was obtained (1.46 g, 94%).
3. 1H NMR (300 MHz, CDCl3): 0.88 (t, J ¼ 6.6 Hz, 6H, –CH3);
1.26–1.32 (m, 60H, –(CH2)15–); 1.80 (m, 4H, –NCH2CH2–); 2.57
(s, 1H, –CCH); 2.78 (s, 6H, Im–CH3); 4.17 (m, 4H, –NCH2–); 4.79
(m, 2H, –OCH2CCH); 5.62 (s, 4H, –CH2–); 7.04 (s, 2H, Im–H);
7.18 (s, 2H, Im–H); 7.21 (s, 1H, Ar-H); 7.97 (s, 2H, Ar-H). 13C (100
MHz, CDCl3): 11.6 (Ar-CH3); 14.3 (–CH3); 32.1–22.8 (–(CH2)13);
49.5 (–CH2–(CH2)13–); 51.5 (–Ar-CH2N–); 56.7 (–CH2–CCH); 78.7
(–CH2CCH); 115.3 (Im1); 121.1 (Im2); 123.7 (Ar2); 122.9 (Ar1);
136.1 (–ArCCH2N–); 144.1 (Im–CH3); 158.3 (–ArCO–). MS (ESI)
(m/z, %): 413.4, [(M  2Br)/2]2+, 100%. Rf: 0.6 (DCM : MeOH
95 : 5). mp: 154 C.
({1,3-Bis[(3-octadecyl-1-imidazolio)methyl]-5-propargyloxy-
benzene}-2-ylidene)gold(I) dibromide (4). LiHMDS (0.86 mmol)
was added to a solution of 2 (200 mg, 0.21 mmol) in dry CH3CN
(40 mL) under argon atmosphere. The resulting orange solution
was stirred for 30 min at room temperature and a solution of
(Me2S)AuCl (70 mg, 0.24 mmol) in CH3CN (10 mL) was added
dropwise. Then the reaction mixture was kept reuxing for 48
hours, aer which the hot yellow transparent solution is let
cooling until room temperature and transferred into the
refrigerator. A grey precipitate formed over 2 hours, which was
collected, washed with diethyl ether (3  10 mL) and hexanes (3
 10 mL), and recrystallized from ethanol–diethylether yielding
a white-yellow solid (90 mg, 40%).
4. 1H NMR (400 MHz, CDCl3): 0.86 (t, J ¼ 6.7 Hz, 6H, –CH3);
1.25–1.31 (m, 60H, –(CH2)15–); 1.88 (m, 4H, –NCH2CH2–); 2.71
(s, 1H, –CCH); 4.14 (t, J ¼ 6.9 Hz, –NCH2–); 4.61 (s, 2H,
–OCH2CCH); 5.20 (s, 4H, –CH2–); 6.61 (s, 2H, Ar-H); 7.09 (s, 1H,
Ar-H); 7.19 (s, 2H, Im–H); 7.44 (s, 2H, Im–H). 13C NMR (100
MHz, DMSO-d6): 0.84 (t, J ¼ 6.7 Hz, 6H, –CH3); 1.18–1.26 (m,
60H, –(CH2)15–); 1.77 (m, 4H, –NCH2CH2–); 3.53 (s, 1H, –CCH);
4.01 (m, 4H, –NCH2–); 4.63 (m, 2H, –OCH2CCH); 5.16 (s, 4H,
–CH2–); 6.51 (s, 1H, Ar-H); 6.72 (s, 2H, Ar-H); 7.50 (s, 2H, Im–H);
7.58 (s, 2H, Im–H). 13C (400 MHz, CDCl3): 14.3 (–CH2(CH2)13-
CH3); 32.1–22.9 (–CH2(CH2)13CH3 + –CH2–); 51.7 (–CH2(CH2)13-
CH3); 54.2 (–Ar-CH2N–); 67.2 (–CH2CCH); 121.8 (Ar1); 123.4
(Ar2); 158.2 (–ArCO–); 191.6 (Im1 + Im2); 207.2 (Im–Au). MS
(MALDI-TOF) (m/z, %): DHB-supported (993.8, [M  H  Br]+,
100%; 955.7, [M  H  Br  CH2CCH]+, 25%); no matrix (993.7,
[M Br]+, 75%; 955.7, [M Br CH2CCH]+, 100%). mp: 220 C.Synthesis of gold nanoparticles
Gold nanoparticles stabilized by imidazolium-based amphi-
philes 2 or 3 were synthesized by modication of the biphasic
Brust–Schiﬀrin method, as described elsewhere.20 Briey,2208 | RSC Adv., 2016, 6, 2202–2209HAuCl4$3H2O solution (27 mg, 0.07 mmol) in water (10 mL) was
mixed, in the dark, with a CH2Cl2 (10 mL) solution of the bis-
imidazolium compound 2 or 3 (50 mg, 0.05 mmol) in an
extraction funnel. The organic phase was collected in a round
bottom ask, and NaBH4 (53 mg, 1.4 mmol) dissolved in water
(5.5 mL) was added with vigorous stirring. The mixture was
stirred at room temperature and in the dark for 4 h. The organic
phase, which presented a dark red colour, was separated using
an extraction funnel and the solvent was evaporated in a rotary
evaporator. The residue was resuspended and washed by
centrifugation with ethanol twice and acetone twice to give
2$AuNP and 3$AuNP as red solid. To store the AuNPs, the solid
was dissolved in CH2Cl2 and the solutions were kept in the dark.Cell culture and antiproliferative eﬀects
HT-29 colon carcinoma and MDA-MB-231 breast adenocarci-
noma cells were maintained in Dulbecco's Modied Eagle's
Medium (DMEM) high glucose (PAA) supplemented with gen-
tamycin (50mg L1) and 10% (v/v) fetal calf serum (FCS) at 37 C
under a 5% CO2 atmosphere and passaged every 7 days. The
antiproliferative eﬀects were determined by the crystal violet
assay as described elsewhere.15 In short: the compounds were
freshly dissolved as stock solutions in dimethylformamide
(DMF) and diluted with cell culture medium to concentrations
in the range of x  y (0.1% v/v DMF). HT-29 and MDA-MB-231
cells were exposed to the drug containing media for a period
of 72 h in an incubator (5% CO2/37 C) and aerwards the cell
biomass was determined by crystal violet staining. The IC50
values were calculated as the concentration required to reduce
cell growth by 50% compared to an untreated control.Acknowledgements
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